European Heart Journal Advance Access originally published online on February 13, 2007
European Heart Journal 2007 28(5):638; doi:10.1093/eurheartj/ehl515
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The European Society of Cardiology 2007. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1 year results of the REPAIR-AMI trial
Marienstr. 9
Amberg 92224
Germany
Tel: +49 962112740 Fax: +49 962112268 E-mail address: karljosef.osterziel@cardiopraxis.com
| The first 10% of the full text of this article appears below. |
The final clinical analysis of the REPAIR-AMI trial is disappointing to me. The authors state that the bone-marrow-derived progenitor cells (BMC) lead to an improvement of function
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. M. Zeiher, V. Schachinger, S. Dimmeler, and For the REPAIR-AMI Investigators Improved clinical outcome after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial: reply Eur. Heart J., September 1, 2007; 28(17): 2173 - 2174. [Full Text] [PDF] |
||||
